文献速递主动脉疾病

连续100例使用Terumo TREO支架行医师改良开窗腔内修复肾旁及胸腹主动脉瘤

One-hundred Consecutive Physician-Modified Fenestrated Endovascular Aneurysm Repair of Pararenal and Thoracoabdominal Aortic Aneurysms Using the Terumo TREO Stent Graft.
PubMed 文献 · Ann Vasc Surg · 2024-05-31

本研究评估单中心连续100例肾旁及胸腹主动脉瘤患者使用Terumo TREO支架行医师改良开窗腔内修复的前瞻性数据,平均年龄73.7岁,技术成功率99%,术后并发症20%,30天死亡2%,2年总生存率87%,结论认为该装置安全有效。

要点

  • 连续100例肾旁或胸腹主动脉瘤患者使用Terumo TREO行医师改良开窗腔内修复,技术成功率99%。
  • 术后并发症发生率20%,30天死亡率2%,I型或III型内漏率2%。
  • 2年总生存率87%,作者认为该装置设计使I型或III型内漏可能性低。

核心结论

  • 使用医师改良开窗Terumo TREO支架治疗肾旁主动脉瘤和IV型胸腹主动脉瘤安全有效,作者认为该装置设计及低I型或III型内漏可能性支持优先使用该装置。

研究设计与样本

  • 前瞻性数据库查询单中心2021年3月至2023年9月连续接受医师改良开窗腔内修复并植入Terumo TREO装置的肾旁及胸腹主动脉瘤患者,共100例。
  • 研究期间共153例患者接受医师改良开窗腔内修复,其中100例使用Terumo TREO支架。

主要发现

  • 平均年龄73.7±7.0岁,高血压94例(94%),冠心病51例(51%),慢性阻塞性肺疾病40例(40%),既往EVAR装置失败34例(34%)。
  • 平均动脉瘤大小66.0±13.7 mm,肾旁主动脉瘤58例(50%),IV型胸腹主动脉瘤30例(30%),症状性或破裂动脉瘤6例(6%)。
  • 每例患者平均 incorporated 靶动脉3.8±0.6条,总体技术成功99%,手术时间218±116分钟,造影剂用量82±21 mL,累积空气比释动能3,054±1,560 mGy。
  • 术后并发症20例(20%),30天内死亡2例(2%),I型或III型内漏率2%,分支血管狭窄或闭塞率1%,再干预率7%,2年总生存率87%。

临床怎么用

  • 原文结论认为该装置安全有效,并支持在此类患者中优先使用Terumo TREO平台。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fenestrated endovascular aortic aneurysm repair (FEVAR) has been widely applied for the treatment of pararenal (PAA) and thoracoabdominal aortic aneurysms (TAAA). If custom-made devices or off-the-shelf devices are not available, physician-modified endografts (PMEGs) are an alternative device option. Several different endograft platforms have been used for PMEG; however, minimal data exists on utilizing the Terumo TREO abdominal stent graft system in this setting. The purpose of this study was to evaluate our single-center experience treating PAA and TAAA, with a physician-modified FEVAR, using the Terumo TREO platform. METHODS: A prospective database of consecutive patients with PAA and TAAA treated at a single center, with a FEVAR, utilizing a PMEG device between March 2021 and September 2023 was queried for those having a Terumo TREO device implanted. The demographics, operative details, and postoperative complications were analyzed. The rates of technical success, type I or III endoleak, branch vessel status, reintervention, and 2-year survival were also assessed. RESULTS: Of the 153 patients who underwent FEVAR with a PMEG device during the study period, 100 had repair using a Terumo TREO stent graft. The mean age of the cohort was 73.7 ± 7.0 years with the majority suffering from hypertension (n = 94, 94%), coronary artery disease (n = 51, 51%), and chronic obstructive pulmonary disease (n = 40, 40%). Thirty-four patients (34%) had a prior failed EVAR device in place. The mean aneurysm size was 66.0 ± 13.7 mm, with 58 (50%) patients classified as PAA and 30 (30%) patients as an extent IV TAAA. Six (6%) patients presented with symptomatic/ruptured aneurysms. The average number of target arteries incorporated per patient was 3.8 ± 0.6. The overall technical success was 99%, procedure time was 218 ± 116 min, contrast volume was 82 ± 21 mL, and cumulative air kerma was 3,054 ± 1,560 mGy. Postoperative complications were present in 20 patients (20%), and 2 patients (2%) died within 30 days. Rates of type I or III endoleak, branch vessel stenosis or occlusion, and reintervention were 2%, 1%, and 7%, respectively. The two-year overall survival was 87%. CONCLUSIONS: Treatment of PAA and the extent IV TAAA using a physician-modified fenestrated Terumo TREO endograft is safe and effective. This large, early experience using the Terumo TREO platform supports preferential use of this device in this setting due to the device design and low likelihood of type I or III endoleak.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nguyen T, Gittinger M, Gryzbowski C, et al. One-hundred Consecutive Physician-Modified Fenestrated Endovascular Aneurysm Repair of Pararenal and Thoracoabdominal Aortic Aneurysms Using the Terumo TREO Stent Graft. Ann Vasc Surg. 2024. PMID: 38823478. doi:10.1016/j.avsg.2024.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。